Tim Clackson

16.6k total citations · 4 hit papers
103 papers, 9.5k citations indexed

About

Tim Clackson is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Tim Clackson has authored 103 papers receiving a total of 9.5k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Molecular Biology, 35 papers in Hematology and 29 papers in Genetics. Recurrent topics in Tim Clackson's work include Chronic Myeloid Leukemia Treatments (30 papers), Chronic Lymphocytic Leukemia Research (26 papers) and Virus-based gene therapy research (25 papers). Tim Clackson is often cited by papers focused on Chronic Myeloid Leukemia Treatments (30 papers), Chronic Lymphocytic Leukemia Research (26 papers) and Virus-based gene therapy research (25 papers). Tim Clackson collaborates with scholars based in United States, United Kingdom and Germany. Tim Clackson's co-authors include James A. Wells, Victor M. Rivera, Greg Winter, Andrew D. Griffiths, Hennie R. Hoogenboom, Roy M. Pollock, Michael Gilman, Dennis A. Holt, Narayana I. Narasimhan and Terence P. Keenan and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Tim Clackson

101 papers receiving 9.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Hot Spot of Binding Energy in a Hormone-Receptor Interface

1995 1.6k citations Tim Clackson et al. profile →
Making antibody fragments using phage display libraries

1991 929 citations Tim Clackson et al. profile →
Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

2012 527 citations Jörge E. Cortes, Hagop M. Kantarjian et al. profile →
By–Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling

1992 314 citations Tim Clackson et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tim Clackson United States	44	6.3k	2.0k	1.7k	1.5k	1.3k	103	9.5k
Abraham M. de Vos United States	48	6.8k 1.1×	2.2k 1.1×	2.6k 1.5×	933 0.6×	571 0.4×	65	10.9k
Stephen C. Blacklow United States	62	11.1k 1.8×	703 0.4×	2.2k 1.2×	899 0.6×	1.4k 1.1×	156	15.9k
Mark Ultsch United States	37	4.9k 0.8×	2.0k 1.0×	1.6k 0.9×	700 0.5×	566 0.4×	62	8.7k
E. Premkumar Reddy United States	63	10.4k 1.7×	775 0.4×	4.8k 2.8×	2.1k 1.4×	1.5k 1.1×	203	17.2k
W. Todd Miller United States	40	4.1k 0.6×	553 0.3×	1.4k 0.8×	500 0.3×	1.4k 1.1×	124	6.5k
Bruce J. Mayer United States	54	9.9k 1.6×	1.3k 0.7×	2.4k 1.4×	891 0.6×	1.0k 0.8×	112	13.6k
Philip E. Thorpe United States	51	5.8k 0.9×	1.4k 0.7×	2.6k 1.5×	395 0.3×	563 0.4×	134	10.6k
Richard A. Gatti United States	58	8.7k 1.4×	697 0.4×	3.2k 1.8×	1.8k 1.2×	605 0.5×	267	12.5k
Keiryn L. Bennett Austria	45	5.8k 0.9×	544 0.3×	1.1k 0.6×	434 0.3×	938 0.7×	120	9.5k
Carlos Garcı́a-Echeverrı́a Switzerland	48	6.7k 1.1×	572 0.3×	2.9k 1.6×	414 0.3×	481 0.4×	130	9.1k

Countries citing papers authored by Tim Clackson

Since Specialization

Citations

This map shows the geographic impact of Tim Clackson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim Clackson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim Clackson more than expected).

Fields of papers citing papers by Tim Clackson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim Clackson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim Clackson. The network helps show where Tim Clackson may publish in the future.

Co-authorship network of co-authors of Tim Clackson

This figure shows the co-authorship network connecting the top 25 collaborators of Tim Clackson. A scholar is included among the top collaborators of Tim Clackson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tim Clackson. Tim Clackson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Park, Miso, Magali Pederzoli-Ribeil, Uğur Eskiocak, et al.. (2023). XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer. Journal for ImmunoTherapy of Cancer. 11(12). e007785–e007785. 8 indexed citations

Cortes, Jörge E., Hagop M. Kantarjian, Javier Pinilla‐Ibarz, et al.. (2017). 5-Year Updates from the Pivotal Phase 2 Ponatinib PACE Trial: Efficacy, Safety and Landmark Analysis in Heavily Pretreated Patients with Chronic-Phase Chronic Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia. 17. S307–S308.

Garner, Andrew P., Joseph M. Gozgit, Rana Anjum, et al.. (2014). Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients. Clinical Cancer Research. 20(22). 5745–5755. 123 indexed citations

Gozgit, Joseph M., Matthew J. Wong, Lauren Moran, et al.. (2012). Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models. Molecular Cancer Therapeutics. 11(3). 690–699. 273 indexed citations

Squillace, Rachel M., David F. Miller, Scott Wardwell, et al.. (2011). Antitumor Activity of Ridaforolimus and Potential Cell-Cycle Determinants of Sensitivity in Sarcoma and Endometrial Cancer Models. Molecular Cancer Therapeutics. 10(10). 1959–1968. 40 indexed citations

Rivera, Victor M., Rachel M. Squillace, David F. Miller, et al.. (2011). Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens. Molecular Cancer Therapeutics. 10(6). 1059–1071. 87 indexed citations

Zheng, Changyu, Antonis Voutetakis, Benjamin I. Goldstein, et al.. (2011). Assessment of the Safety and Biodistribution of a Regulated AAV2 Gene Transfer Vector after Delivery to Murine Submandibular Glands. Toxicological Sciences. 123(1). 247–255. 4 indexed citations

Squillace, Rachel M., David F. Miller, Tim Clackson, & Victor M. Rivera. (2008). Anti-proliferative activity of the mTOR inhibitor deforolimus (AP23573; MK-8669) in combination with cytotoxic and targeted agents in sarcoma and endometrial cancer models. Cancer Research. 68. 4006–4006. 1 indexed citations

Clackson, Tim & Henry B. Lowman. (2004). Phage display : a practical approach. Oxford University Press eBooks. 82 indexed citations

10.

Metcalf, Chester A., Regine S. Bohacek, Leonard W. Rozamus, et al.. (2004). Structure-based design of AP23573, a phosphorus-containing analog of rapamycin for anti-tumor therapy.. Cancer Research. 64. 573–573. 19 indexed citations

11.

Rivera, Victor M., Hao Tang, Chester A. Metcalf, et al.. (2004). Anti-proliferative activity of the mTOR inhibitor AP23573 in combination with cytotoxic and targeted agents. Cancer Research. 64. 896–896. 18 indexed citations

12.

Rivera, Victor M., Guangping Gao, Rebecca Grant, et al.. (2004). Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood. 105(4). 1424–1430. 225 indexed citations

13.

Johnston, Julie, John Tazelaar, Victor M. Rivera, et al.. (2003). Regulated expression of erythropoietin from an AAV vector safely improves the anemia of β-thalassemia in a mouse model. Molecular Therapy. 7(4). 493–497. 44 indexed citations

14.

Pollock, Roy M. & Tim Clackson. (2002). Dimerizer-regulated gene expression. Current Opinion in Biotechnology. 13(5). 459–467. 82 indexed citations

15.

Chong, Heung, et al.. (2002). A System for Small-Molecule Control of Conditionally Replication-Competent Adenoviral Vectors. Molecular Therapy. 5(2). 195–203. 39 indexed citations

16.

Clackson, Tim. (2000). Regulated gene expression systems. Gene Therapy. 7(2). 120–125. 113 indexed citations

17.

Wu, Yang, Leonard W. Rozamus, Surinder S. Narula, et al.. (2000). Investigating Protein−Ligand Interactions with a Mutant FKBP Possessing a Designed Specificity Pocket. Journal of Medicinal Chemistry. 43(6). 1135–1142. 73 indexed citations

18.

Volchuk, Allen, M Amherdt, Mariella Ravazzola, et al.. (2000). Megavesicles Implicated in the Rapid Transport of Intracisternal Aggregates across the Golgi Stack. Cell. 102(3). 335–348. 93 indexed citations

19.

Rivera, Victor M., Tim Clackson, Sridaran Natesan, et al.. (1996). A humanized system for pharmacologic control of gene expression. Nature Medicine. 2(9). 1028–1032. 433 indexed citations

20.

Clackson, Tim, et al.. (1989). Direct clone characterization from plaques and colonies by the polymerase chain reaction. Nucleic Acids Research. 17(10). 4000–4000. 289 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact